RU2110993C1 - Синергетическая фармацевтическая комбинация, фармацевтическая композиция и способ лечения или профилактики вич-инфекций - Google Patents

Синергетическая фармацевтическая комбинация, фармацевтическая композиция и способ лечения или профилактики вич-инфекций Download PDF

Info

Publication number
RU2110993C1
RU2110993C1 RU93045710A RU93045710A RU2110993C1 RU 2110993 C1 RU2110993 C1 RU 2110993C1 RU 93045710 A RU93045710 A RU 93045710A RU 93045710 A RU93045710 A RU 93045710A RU 2110993 C1 RU2110993 C1 RU 2110993C1
Authority
RU
Russia
Prior art keywords
combination
hiv
components
fluorocytosine
treatment
Prior art date
Application number
RU93045710A
Other languages
English (en)
Russian (ru)
Other versions
RU93045710A (ru
Inventor
Роберт Пейнтер Джордж
Аллен Фурман Филип
Original Assignee
Дзе Велкам Фаундейшн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Велкам Фаундейшн Лимитед filed Critical Дзе Велкам Фаундейшн Лимитед
Publication of RU93045710A publication Critical patent/RU93045710A/ru
Application granted granted Critical
Publication of RU2110993C1 publication Critical patent/RU2110993C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
RU93045710A 1991-03-06 1992-03-05 Синергетическая фармацевтическая комбинация, фармацевтическая композиция и способ лечения или профилактики вич-инфекций RU2110993C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9104740.7 1991-03-06
GB919104740A GB9104740D0 (en) 1991-03-06 1991-03-06 Antiviral nucleoside combination
PCT/GB1992/000389 WO1992015309A1 (en) 1991-03-06 1992-03-05 Antiviral nucleoside combination

Publications (2)

Publication Number Publication Date
RU93045710A RU93045710A (ru) 1996-11-10
RU2110993C1 true RU2110993C1 (ru) 1998-05-20

Family

ID=10691101

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93045710A RU2110993C1 (ru) 1991-03-06 1992-03-05 Синергетическая фармацевтическая комбинация, фармацевтическая композиция и способ лечения или профилактики вич-инфекций

Country Status (25)

Country Link
US (2) US5234913A (enExample)
EP (1) EP0574457B1 (enExample)
JP (1) JP3442773B2 (enExample)
KR (1) KR100225986B1 (enExample)
AT (1) ATE185483T1 (enExample)
AU (1) AU668860B2 (enExample)
CA (1) CA2105487C (enExample)
CZ (1) CZ283185B6 (enExample)
DE (1) DE69230140T2 (enExample)
DK (1) DK0574457T3 (enExample)
ES (1) ES2138969T3 (enExample)
GB (1) GB9104740D0 (enExample)
GR (1) GR3032299T3 (enExample)
HU (1) HU219492B (enExample)
IE (1) IE920702A1 (enExample)
IL (1) IL101145A (enExample)
MY (1) MY108638A (enExample)
NZ (1) NZ241842A (enExample)
PT (1) PT100199B (enExample)
RU (1) RU2110993C1 (enExample)
SK (1) SK279767B6 (enExample)
TW (1) TW199861B (enExample)
UA (1) UA29429C2 (enExample)
WO (1) WO1992015309A1 (enExample)
ZA (1) ZA921660B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017763B1 (ru) * 2004-07-09 2013-03-29 Джилид Сайэнс, Инк. Фармацевтический вагинальный гель

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
DE69206876T3 (de) * 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1995024904A1 (en) * 1994-03-16 1995-09-21 Tanox Biosystems, Inc. Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
ATE346651T1 (de) * 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
ATE230267T1 (de) * 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
ATE267198T1 (de) * 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
WO1998044913A2 (en) 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
US6040434A (en) * 1997-12-01 2000-03-21 Inaba; Tadanobu Aldehyde oxidase inhibitors for treatment of aids
BR9911457A (pt) * 1998-06-24 2001-12-11 Univ Emory Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
JP4249393B2 (ja) 1998-08-12 2009-04-02 トライアングル・ファーマシューティカルズ，インコーポレイテッド １，３−オキサチオランヌクレオチドの製造方法
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ES2314157T3 (es) * 1998-11-02 2009-03-16 Gilead Sciences, Inc. Terapia de combinacion para tratar el virus de la hepatitis b.
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
PT1574512E (pt) * 2001-03-01 2008-03-05 Abbott Lab Formas polimórficas e outras formas cristalinas de cis-ftc

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650130T3 (de) * 1985-03-16 2003-07-24 The Wellcome Foundation Ltd., London Antivirale Nukleoside.
US4874751A (en) * 1985-03-16 1989-10-17 Burroughs Wellcome Co. Antibacterial treatment
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
ZA878877B (en) * 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
US4837311A (en) * 1987-06-22 1989-06-06 Hoffman-La Roche Inc. Anti-retroviral compounds
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
WO1990014079A1 (en) * 1989-05-15 1990-11-29 The United States Of America, Represented By The Secretary, United States Department Of Commerce Method of treatment of hepatitis
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
IT1249019B (it) * 1990-06-28 1995-02-11 Lamberti S P A L Emulsione acquosa di resine filmogene per la finitura di pelli, cuoio e croste di pelle e relativo procedimento di applicazione
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DE69206876T3 (de) * 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SU 1442076 А3 (Эли Лилли энд Компани), 30.11.88, A 61 K 31/70. SU 1548182 А1 (Институт молекулярной биологии АН СССР и др.), 07.03.90, A 61 K 31/70. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017763B1 (ru) * 2004-07-09 2013-03-29 Джилид Сайэнс, Инк. Фармацевтический вагинальный гель

Also Published As

Publication number Publication date
WO1992015309A1 (en) 1992-09-17
US6107288A (en) 2000-08-22
ZA921660B (en) 1993-09-06
HU219492B (hu) 2001-04-28
DE69230140T2 (de) 2000-04-06
CA2105487A1 (en) 1992-09-07
SK279767B6 (sk) 1999-03-12
HU9302496D0 (en) 1993-11-29
KR100225986B1 (ko) 1999-10-15
IE920702A1 (en) 1992-09-09
CZ183693A3 (en) 1994-06-15
JPH06506199A (ja) 1994-07-14
CZ283185B6 (cs) 1998-01-14
ATE185483T1 (de) 1999-10-15
NZ241842A (en) 1994-08-26
PT100199A (pt) 1993-07-30
PT100199B (pt) 1999-06-30
GB9104740D0 (en) 1991-04-17
IL101145A0 (en) 1992-11-15
IL101145A (en) 1996-08-04
EP0574457A1 (en) 1993-12-22
MY108638A (en) 1996-10-31
DE69230140D1 (de) 1999-11-18
ES2138969T3 (es) 2000-02-01
EP0574457B1 (en) 1999-10-13
AU1351292A (en) 1992-10-06
TW199861B (enExample) 1993-02-11
HUT72460A (en) 1996-04-29
UA29429C2 (uk) 2000-11-15
AU668860B2 (en) 1996-05-23
JP3442773B2 (ja) 2003-09-02
HK1004189A1 (en) 1998-11-20
DK0574457T3 (da) 2000-04-17
CA2105487C (en) 2002-09-24
GR3032299T3 (en) 2000-04-27
SK95193A3 (en) 1994-01-12
US5234913A (en) 1993-08-10

Similar Documents

Publication Publication Date Title
US6107288A (en) Antiviral nucleoside combination
RU2116789C1 (ru) Способ ингибирования вирусных инфекций гепатита в
KR960007532B1 (ko) 1,3-옥사티오란 뉴클레오시드 동족체
JPH08507286A (ja) 選択的な抗Ｂ型肝炎ウイルス活性を有する鏡像体的に純粋なβ−Ｄ−ジオキソランヌクレオシド
JP2818299B2 (ja) ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用
EP0777669B1 (en) 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-1-methanol succinate as antiviral agent
RU2104700C1 (ru) Способ лечения гепатита в
US20080187580A1 (en) Therapeutic nucleosides
HK1004189B (en) Antiviral nucleoside combination
MC1766A1 (fr) Procede pour la preparation de 3'-azido-nucleosides et procede pour preparer des formulations pharmaceutiques les contenant
CA2439322A1 (en) Therapeutic nucleosides